Amit Syal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amit Syal has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Laila Elias
Department of Urology, Mayo Clinic Hospital, Phoenix, USA
4 shared publications- Chris T. Derk
Division of Rheumatology, University of Pennsylvania, Philadelphia, USA
3 shared publications - Stavropoula Tjoumakaris
Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
3 shared publications Anojan K. Navaratnam
Department of Urology, Mayo Clinic Hospital, Phoenix, USA
2 shared publicationsAnojan Navaratnam
Phoenix, AZ
2 shared publications- David G. Lott
Division of Laryngology Mayo Clinic Arizona Phoenix Arizona USA
2 shared publications
Latest Publications
- 1 October 2026
- Published byĀ ElsevierĀ inĀ Clinical Colorectal Cancer
Early-Onset Colorectal Cancer: Epidemiology, Etiologic Pathways, and Emerging Prevention Strategies
- 1 October 2026
- Published byĀ ElsevierĀ inĀ Clinical Colorectal Cancer
Early-Onset Colorectal Cancer: Epidemiology, Etiologic Pathways, and Emerging Prevention Strategies
- Open Access
- 10 September 2026
- Published byĀ IMR PressĀ inĀ British Journal of Hospital Medicine
- Vol.Ā 87 Ā (9)
Gastrointestinal Manifestations of Systemic Sclerosis: Screening and Management to Improve Outcomes
Gastrointestinal (GI) involvement is among the most common and clinically important manifestations of systemic sclerosis (SSc), affecting up to 90% of patients and substantially contributing to morbidity and reduced quality of life. SSc-related GI disease results from microvascular injury, enteric nervous system dysfunction, and progressive smooth muscle atrophy with fibrosis, producing widespread dysmotility throughout the gastrointestinal tract. Clinical involvement can extend from the oral cavity to the anorectum, with esophageal dysfunction, gastroesophageal reflux disease (GERD), gastroparesis, small intestinal bacterial overgrowth (SIBO), and intestinal pseudo-obstruction among the major manifestations. Recent diagnostic advances, including high-resolution esophageal manometry (HRM), ambulatory pH-impedance monitoring, and improved imaging, have strengthened early detection and characterization of GI involvement. Treatment remains largely supportive and symptom-directed, including acid suppression, prokinetic therapy, nutritional optimization, and endoscopic or surgical management of complications. Growing evidence on the gut microbiome, immune-mediated mechanisms, and the gut-brain axis is expanding understanding of disease pathophysiology and may guide future targeted therapies. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical manifestations, and management of gastrointestinal involvement in systemic sclerosis, emphasizing early recognition and multidisciplinary care. We conclude by outlining persistent management challenges and future directions to improve diagnostic precision, therapeutic development, and patient-centered outcomes.
- 10 September 2026
- Published byĀ IMR PressĀ inĀ British Journal of Hospital Medicine
- Vol.Ā 87 Ā (9)
Open AccessGastrointestinal Manifestations of Systemic Sclerosis: Screening and Management to Improve Outcomes
Gastrointestinal (GI) involvement is among the most common and clinically important manifestations of systemic sclerosis (SSc), affecting up to 90% of patients and substantially contributing to morbidity and reduced quality of life. SSc-related GI disease results from microvascular injury, enteric nervous system dysfunction, and progressive smooth muscle atrophy with fibrosis, producing widespread dysmotility throughout the gastrointestinal tract. Clinical involvement can extend from the oral cavity to the anorectum, with esophageal dysfunction, gastroesophageal reflux disease (GERD), gastroparesis, small intestinal bacterial overgrowth (SIBO), and intestinal pseudo-obstruction among the major manifestations. Recent diagnostic advances, including high-resolution esophageal manometry (HRM), ambulatory pH-impedance monitoring, and improved imaging, have strengthened early detection and characterization of GI involvement. Treatment remains largely supportive and symptom-directed, including acid suppression, prokinetic therapy, nutritional optimization, and endoscopic or surgical management of complications. Growing evidence on the gut microbiome, immune-mediated mechanisms, and the gut-brain axis is expanding understanding of disease pathophysiology and may guide future targeted therapies. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical manifestations, and management of gastrointestinal involvement in systemic sclerosis, emphasizing early recognition and multidisciplinary care. We conclude by outlining persistent management challenges and future directions to improve diagnostic precision, therapeutic development, and patient-centered outcomes.
- 24 August 2026
- Published byĀ Wolters Kluwer HealthĀ inĀ JCR: Journal of Clinical Rheumatology
Systemic Sclerosisāassociated Interstitial Lung Disease at 2 Tertiary Centers in the USA and Greece: A Comparative Study of Demographics, Management, and Radiologic Progression
Objective: To compare demographics, clinical features, treatment approaches, and outcomes of patients with systemic sclerosis-interstitial lung disease (SSc-ILD) at 2 geographically distinct tertiary centers: the University of Pennsylvania (UPenn), USA, and the University of Ioannina (UOI), Greece. Methods: A cohort of 789 SSc patients (2013 ACR/EULAR criteria) was evaluated through medical records review at both institutions. Patients initially diagnosed with SSc-ILD between January 2020 and December 2024 with at least 72 weeks of follow-up were included. Sociodemographic, clinical, serological, and treatment data were systematically collected. ILD progression was defined as radiographic worsening on serial HRCTācomprising new or increased ground-glass opacification, reticulation, or traction bronchiectasisāas assessed at each center. PFTs were obtained at baseline and at 24, 48, and 72 weeks. Results: Sixty-six patients were included (35 UPenn, 31 UOI). Arthritis (32.3% vs. 11.4%) and anti-Scl-70 positivity (64.5% vs. 40.0%) were more frequent at UOI. UOI patients had higher rates of rituximab (35.5% vs. 5.7%) and corticosteroid use (77.4% vs. 42.9%). ILD progression at 48 weeks was significantly greater in UPenn (57.1% vs. 17.2%, p p =0.001). On multivariate analysis, dcSSc, male sex, and study center were independent predictors of ILD progression. Conclusions: This study compares SSc-ILD presentation, management, and outcomes at 2 tertiary centers. UPenn showed a higher radiologic ILD progression rate, likely due to baseline disease severity, treatment differences, and referral timing. Nonetheless, these findings are observational; prospective, internationally standardized studies are needed to confirm these results.
- 24 August 2026
- Published byĀ Wolters Kluwer HealthĀ inĀ JCR: Journal of Clinical Rheumatology
Systemic Sclerosisāassociated Interstitial Lung Disease at 2 Tertiary Centers in the USA and Greece: A Comparative Study of Demographics, Management, and Radiologic Progression
Objective: To compare demographics, clinical features, treatment approaches, and outcomes of patients with systemic sclerosis-interstitial lung disease (SSc-ILD) at 2 geographically distinct tertiary centers: the University of Pennsylvania (UPenn), USA, and the University of Ioannina (UOI), Greece. Methods: A cohort of 789 SSc patients (2013 ACR/EULAR criteria) was evaluated through medical records review at both institutions. Patients initially diagnosed with SSc-ILD between January 2020 and December 2024 with at least 72 weeks of follow-up were included. Sociodemographic, clinical, serological, and treatment data were systematically collected. ILD progression was defined as radiographic worsening on serial HRCTācomprising new or increased ground-glass opacification, reticulation, or traction bronchiectasisāas assessed at each center. PFTs were obtained at baseline and at 24, 48, and 72 weeks. Results: Sixty-six patients were included (35 UPenn, 31 UOI). Arthritis (32.3% vs. 11.4%) and anti-Scl-70 positivity (64.5% vs. 40.0%) were more frequent at UOI. UOI patients had higher rates of rituximab (35.5% vs. 5.7%) and corticosteroid use (77.4% vs. 42.9%). ILD progression at 48 weeks was significantly greater in UPenn (57.1% vs. 17.2%, p p =0.001). On multivariate analysis, dcSSc, male sex, and study center were independent predictors of ILD progression. Conclusions: This study compares SSc-ILD presentation, management, and outcomes at 2 tertiary centers. UPenn showed a higher radiologic ILD progression rate, likely due to baseline disease severity, treatment differences, and referral timing. Nonetheless, these findings are observational; prospective, internationally standardized studies are needed to confirm these results.
- Open Access
- 22 June 2026
- Published byĀ Springer NatureĀ inĀ Rheumatology International
- Vol.Ā 46 Ā (7)
Pruritus associated with systemic sclerosis: a systematic review of treatment-based clinical trials
This paper aims to examine the latest research on treatments for itch (pruritus) in people with systemic sclerosis (SSc), identify areas where information is lacking, and propose suggestions for future studies.A comprehensive literature search was performed in PubMed and Scopus in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify studies evaluating therapeutic interventions for pruritus in SSc. Eligible studies included randomized controlled trials, cohort studies, and case series comprising a minimum of three patients. Data extraction encompassed study design, patient demographics, pruritus assessment instruments including validated and non-validated measures, and clinical outcomes. Studies were excluded if they concerned localized scleroderma, irrelevant populations, case reports, systematic reviews, lacking relevant outcome data, or incomplete trials. Ten studies met criteria, evaluating immunomodulatory agents, mast cell stabilizers, opioid receptor antagonist, and lysophosphatidic acid receptor antagonists. Pruritus assessment varied and was often secondary to fibrosis outcomes. Oral lenabasum improved pruritus in a phase II trial; low-dose opioid receptor modulators and rituximab also showed qualitative improvement. Pruritus is a frequently overlooked yet clinically significant symptom in systemic sclerosis (SSc) that negatively impacts patientsā quality of life. Existing evidence regarding effective therapeutic options remains limited. Future research should prioritize pruritus as a predefined outcome and utilize validated assessment instruments to inform treatment strategies and enhance patient quality of life.
- 22 June 2026
- Published byĀ Springer NatureĀ inĀ Rheumatology International
- Vol.Ā 46 Ā (7)
Open AccessPruritus associated with systemic sclerosis: a systematic review of treatment-based clinical trials
This paper aims to examine the latest research on treatments for itch (pruritus) in people with systemic sclerosis (SSc), identify areas where information is lacking, and propose suggestions for future studies.A comprehensive literature search was performed in PubMed and Scopus in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify studies evaluating therapeutic interventions for pruritus in SSc. Eligible studies included randomized controlled trials, cohort studies, and case series comprising a minimum of three patients. Data extraction encompassed study design, patient demographics, pruritus assessment instruments including validated and non-validated measures, and clinical outcomes. Studies were excluded if they concerned localized scleroderma, irrelevant populations, case reports, systematic reviews, lacking relevant outcome data, or incomplete trials. Ten studies met criteria, evaluating immunomodulatory agents, mast cell stabilizers, opioid receptor antagonist, and lysophosphatidic acid receptor antagonists. Pruritus assessment varied and was often secondary to fibrosis outcomes. Oral lenabasum improved pruritus in a phase II trial; low-dose opioid receptor modulators and rituximab also showed qualitative improvement. Pruritus is a frequently overlooked yet clinically significant symptom in systemic sclerosis (SSc) that negatively impacts patientsā quality of life. Existing evidence regarding effective therapeutic options remains limited. Future research should prioritize pruritus as a predefined outcome and utilize validated assessment instruments to inform treatment strategies and enhance patient quality of life.
- 28 December 2023
- Published byĀ SAGE PublicationsĀ inĀ Interventional Neuroradiology
- Vol.Ā 32 Ā (3) , 553-563
The Enterprise stentā¦still useful after all these years
Background: The Enterprise stent (Codman Neuro, Massachusetts, USA) received Food and Drug Administration (FDA) approval in 2007 for stent-assisted coiling (SAC). Since its introduction, newer stents and devices for aneurysm treatment have been developed resulting in a shift in the utilization of this stent from SAC to other off-label indications. Objective: To describe our experience with the Enterprise stent being used for SAC and other off-label indications. Methods: This is a multi-center retrospective review of the use of the Enterprise stent between 2018 and 2023. All patients in which the Enterprise stent was successfully deployed were included in the study. Results: Our study cohort comprised of 194 patients, mostly females (n = 112, 57.7%), with a mean age of 63.2 years ± 14.3. The Enterprise stent was used for SAC in only 24 (12.4%) patients and was used for rescue stenting in stroke in 101 patients (52.1%), treatment of intracranial stenosis in 53 patients (27.3%), treatment of in-stent stenosis in 1 patient (0.5%), and for treatment of dissections in 15 patients (7.7%). From 2018 to 2023, the use of Enterprise stents for SAC significantly decreased ( p < 0.0001) while the use of Enterprise stents for non-SAC purposes was insignificantly variable ( p = 0.05). Conclusion: Our study shows that the Enterprise stent remains a reliable tool in neuroendovascular procedures, even if its original intended use has been supplanted by other devices.
- 28 December 2023
- Published byĀ SAGE PublicationsĀ inĀ Interventional Neuroradiology
- Vol.Ā 32 Ā (3) , 553-563
The Enterprise stentā¦still useful after all these years
Background: The Enterprise stent (Codman Neuro, Massachusetts, USA) received Food and Drug Administration (FDA) approval in 2007 for stent-assisted coiling (SAC). Since its introduction, newer stents and devices for aneurysm treatment have been developed resulting in a shift in the utilization of this stent from SAC to other off-label indications. Objective: To describe our experience with the Enterprise stent being used for SAC and other off-label indications. Methods: This is a multi-center retrospective review of the use of the Enterprise stent between 2018 and 2023. All patients in which the Enterprise stent was successfully deployed were included in the study. Results: Our study cohort comprised of 194 patients, mostly females (n = 112, 57.7%), with a mean age of 63.2 years ± 14.3. The Enterprise stent was used for SAC in only 24 (12.4%) patients and was used for rescue stenting in stroke in 101 patients (52.1%), treatment of intracranial stenosis in 53 patients (27.3%), treatment of in-stent stenosis in 1 patient (0.5%), and for treatment of dissections in 15 patients (7.7%). From 2018 to 2023, the use of Enterprise stents for SAC significantly decreased ( p < 0.0001) while the use of Enterprise stents for non-SAC purposes was insignificantly variable ( p = 0.05). Conclusion: Our study shows that the Enterprise stent remains a reliable tool in neuroendovascular procedures, even if its original intended use has been supplanted by other devices.
- Open Access
- 30 July 2023
- Published byĀ BMJ
- Vol.Ā 15 Ā (Suppl 1) , A204.2-A205
E-212 A comparison of outcomes between transfemoral versus transradial access for carotid stenting
Background The transradial (TR) approach has emerged as an alternative to the transfemoral (TR) approach in carotid artery stenting (CAS) due to its perceived benefits in access site complications and overall patient experience. Objective To assess outcomes of transfemoral vs transradial approach for carotid artery stenting. Methods This is a retrospective single-center review of patients receiving CAS via the TR or TF route between 2017 and 2022. All patients with symptomatic and asymptomatic carotid disease who underwent attempted CAS were included in our study. Results A total of 342 patients are included in the study: 232 underwent CAS via TF approach vs 110 via the TR route. On univariate analysis, the rate of overall complications was more than double for the TF vs TR cohort, however this did not achieve statistical significance (6.5%vs2.7%, OR=0.59 p=.36). The rate of cross-over from TR to TF was significantly higher on univariate analysis (14.6%vs2.6%, OR=4.77, p=.005) and on inverse probability treatment weighting analysis (OR= 6.11, p<.001). The rate of in-stent stenosis (TR:3.6% vs TF:2.2%, OR=1.71, p=.43) and strokes at follow-up (TF:2.2% vs TR:1.8%, OR= 0.84, p=.84) was not significantly different. Lastly, median length of stay was comparable between both cohorts. Conclusion The TR approach is safe, feasible, and provides similar rates of complications and high rates of successful stent deployment compared with the TF route. Neurointerventionalists adopting the radial first approach should carefully assess the pre-procedural computed tomography angiography to identify patients amenable to TR approach for carotid stenting. Comparison of outcomes between trans-radial vs trans-femoral access Disclosures K. El Naamani: None. O. Khanna: None. A. Syal: None. A. Momin: None. R. Abbas: None. A. Amllay: None. A. Sambangi: None. A. Hunt: None. J. Dougherty: None. C. Lawall: None. S. Tjoumakaris: 2; C; Microvention, Medtronic. M. Gooch: 2; C; Stryker. N. Herial: None. R. Rosenwasser: None. H. Zarzour: None. R. Schmidt: None. P. Jabbour: 2; C; Microvention, Medtronic, Balt, Ceres Endovascular.
- 30 July 2023
- Published byĀ BMJ
- Vol.Ā 15 Ā (Suppl 1) , A204.2-A205
Open AccessE-212 A comparison of outcomes between transfemoral versus transradial access for carotid stenting
Background The transradial (TR) approach has emerged as an alternative to the transfemoral (TR) approach in carotid artery stenting (CAS) due to its perceived benefits in access site complications and overall patient experience. Objective To assess outcomes of transfemoral vs transradial approach for carotid artery stenting. Methods This is a retrospective single-center review of patients receiving CAS via the TR or TF route between 2017 and 2022. All patients with symptomatic and asymptomatic carotid disease who underwent attempted CAS were included in our study. Results A total of 342 patients are included in the study: 232 underwent CAS via TF approach vs 110 via the TR route. On univariate analysis, the rate of overall complications was more than double for the TF vs TR cohort, however this did not achieve statistical significance (6.5%vs2.7%, OR=0.59 p=.36). The rate of cross-over from TR to TF was significantly higher on univariate analysis (14.6%vs2.6%, OR=4.77, p=.005) and on inverse probability treatment weighting analysis (OR= 6.11, p<.001). The rate of in-stent stenosis (TR:3.6% vs TF:2.2%, OR=1.71, p=.43) and strokes at follow-up (TF:2.2% vs TR:1.8%, OR= 0.84, p=.84) was not significantly different. Lastly, median length of stay was comparable between both cohorts. Conclusion The TR approach is safe, feasible, and provides similar rates of complications and high rates of successful stent deployment compared with the TF route. Neurointerventionalists adopting the radial first approach should carefully assess the pre-procedural computed tomography angiography to identify patients amenable to TR approach for carotid stenting. Comparison of outcomes between trans-radial vs trans-femoral access Disclosures K. El Naamani: None. O. Khanna: None. A. Syal: None. A. Momin: None. R. Abbas: None. A. Amllay: None. A. Sambangi: None. A. Hunt: None. J. Dougherty: None. C. Lawall: None. S. Tjoumakaris: 2; C; Microvention, Medtronic. M. Gooch: 2; C; Stryker. N. Herial: None. R. Rosenwasser: None. H. Zarzour: None. R. Schmidt: None. P. Jabbour: 2; C; Microvention, Medtronic, Balt, Ceres Endovascular.
- 28 July 2023
- Published byĀ ElsevierĀ inĀ Clinical Neurology and Neurosurgery
- Vol.Ā 233, 107916
Predictors of Transfemoral Access Site Complications in Neuroendovascular Procedures: A large Single-Center Cohort Study
- 28 July 2023
- Published byĀ ElsevierĀ inĀ Clinical Neurology and Neurosurgery
- Vol.Ā 233, 107916
Predictors of Transfemoral Access Site Complications in Neuroendovascular Procedures: A large Single-Center Cohort Study
- 26 November 2022
- Published byĀ SAGE PublicationsĀ inĀ Annals of Otology, Rhinology & Laryngology
- Vol.Ā 132 Ā (10) , 1261-1264
Radiation-Induced Laryngeal Mucous Membrane Pemphigoid
Objectives: Bullous pemphigoid has previously been linked to radiotherapy, but here we report the first case of MMP suspected to be a consequence of RT. Methods: The patient described is an 85-year-old male who underwent RT to treat squamous cell carcinoma of the palatine tonsil. Shortly after therapy, the patient developed blisters with worsening dyspnea and dysphonia. Results: This patient was successfully treated with a combination of oral immunosuppressants and surgical intervention. Conclusion: This incident underscores that not all episodes of mucosal ulceration following radiation are a result of mucositis and MMP should be considered in the differential. Level of evidence: Level 4.
- 26 November 2022
- Published byĀ SAGE PublicationsĀ inĀ Annals of Otology, Rhinology & Laryngology
- Vol.Ā 132 Ā (10) , 1261-1264
Radiation-Induced Laryngeal Mucous Membrane Pemphigoid
Objectives: Bullous pemphigoid has previously been linked to radiotherapy, but here we report the first case of MMP suspected to be a consequence of RT. Methods: The patient described is an 85-year-old male who underwent RT to treat squamous cell carcinoma of the palatine tonsil. Shortly after therapy, the patient developed blisters with worsening dyspnea and dysphonia. Results: This patient was successfully treated with a combination of oral immunosuppressants and surgical intervention. Conclusion: This incident underscores that not all episodes of mucosal ulceration following radiation are a result of mucositis and MMP should be considered in the differential. Level of evidence: Level 4.
- Open Access
- 16 August 2022
- Published byĀ MDPI AGĀ inĀ International Journal of Environmental Research and Public Health
- Vol.Ā 19 Ā (16) , 10158
Evaluating the Impact of Modic Changes on Operative Treatment in the Cervical and Lumbar Spine: A Systematic Review and Meta-Analysis
Modic changes (MCs) are believed to be potential pain generators in the lumbar and cervical spine, but it is currently unclear if their presence affects postsurgical outcomes. We performed a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. All studies evaluating cervical or lumbar spine postsurgical outcomes in patients with documented preoperative MCs were included. A total of 29 studies and 6013 patients with 2688 of those patients having preoperative MCs were included. Eight included studies evaluated cervical spine surgery, eleven evaluated lumbar discectomies, nine studied lumbar fusion surgery, and three assessed lumbar disc replacements. The presence of cervical MCs did not impact the clinical outcomes in the cervical spine procedures. Moreover, most studies found that MCs did not significantly impact the clinical outcomes following lumbar fusion, lumbar discectomy, or lumbar disc replacement. A meta-analysis of the relevant data found no significant association between MCs and VAS back pain or ODI following lumbar discectomy. Similarly, there was no association between MCs and JOA or neck pain following ACDF procedures. Patients with MC experienced statistically significant improvements following lumbar or cervical spine surgery. The postoperative improvements were similar to patients without MCs in the cervical and lumbar spine.
- 16 August 2022
- Published byĀ MDPI AGĀ inĀ International Journal of Environmental Research and Public Health
- Vol.Ā 19 Ā (16) , 10158
Open AccessEvaluating the Impact of Modic Changes on Operative Treatment in the Cervical and Lumbar Spine: A Systematic Review and Meta-Analysis
Modic changes (MCs) are believed to be potential pain generators in the lumbar and cervical spine, but it is currently unclear if their presence affects postsurgical outcomes. We performed a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. All studies evaluating cervical or lumbar spine postsurgical outcomes in patients with documented preoperative MCs were included. A total of 29 studies and 6013 patients with 2688 of those patients having preoperative MCs were included. Eight included studies evaluated cervical spine surgery, eleven evaluated lumbar discectomies, nine studied lumbar fusion surgery, and three assessed lumbar disc replacements. The presence of cervical MCs did not impact the clinical outcomes in the cervical spine procedures. Moreover, most studies found that MCs did not significantly impact the clinical outcomes following lumbar fusion, lumbar discectomy, or lumbar disc replacement. A meta-analysis of the relevant data found no significant association between MCs and VAS back pain or ODI following lumbar discectomy. Similarly, there was no association between MCs and JOA or neck pain following ACDF procedures. Patients with MC experienced statistically significant improvements following lumbar or cervical spine surgery. The postoperative improvements were similar to patients without MCs in the cervical and lumbar spine.
- 21 January 2022
- Published byĀ WileyĀ inĀ The Laryngoscope
- Vol.Ā 132 Ā (11) , 2187-2193
Prognostic and Treatment Differences Between T1a and T1b Glottic Cancer
Objectives: This study was designed to evaluate significant differences in treatment and survival outcomes between patients with T1a and T1b glottic cancer.Methods: Patients within the SEER Research Plus, 18 Registries dataset who were diagnosed with Stage I T1a or T1b cancer of the glottis between 2004 and 2015 were included in this study. Data prior to 2004 could not be included, as the SEER database did not distinguish between T1a and T1b glottic cancer until that year.Results: The 5āyear diseaseāspecific survival for T1a patients was significantly better than that of patients diagnosed with T1b glottic cancer. Age and year of diagnosis were also independent factors that impacted mortality. More patients who were diagnosed with T1b glottic cancer underwent external beam radiation than those diagnosed with T1a glottic cancer.Conclusion: Our data shows that there are several independent factors effecting mortality including T classification, age at time of diagnosis, and year of diagnosis. T1a glottic cancers also show a significantly better prognosis compared with T1b. T1b glottic cancers are much more likely to be treated with primary radiotherapy compared with surgery.Level of Evidence: 4 Laryngoscope, 132:2187ā2193, 2022
- 21 January 2022
- Published byĀ WileyĀ inĀ The Laryngoscope
- Vol.Ā 132 Ā (11) , 2187-2193
Prognostic and Treatment Differences Between T1a and T1b Glottic Cancer
Objectives: This study was designed to evaluate significant differences in treatment and survival outcomes between patients with T1a and T1b glottic cancer.Methods: Patients within the SEER Research Plus, 18 Registries dataset who were diagnosed with Stage I T1a or T1b cancer of the glottis between 2004 and 2015 were included in this study. Data prior to 2004 could not be included, as the SEER database did not distinguish between T1a and T1b glottic cancer until that year.Results: The 5āyear diseaseāspecific survival for T1a patients was significantly better than that of patients diagnosed with T1b glottic cancer. Age and year of diagnosis were also independent factors that impacted mortality. More patients who were diagnosed with T1b glottic cancer underwent external beam radiation than those diagnosed with T1a glottic cancer.Conclusion: Our data shows that there are several independent factors effecting mortality including T classification, age at time of diagnosis, and year of diagnosis. T1a glottic cancers also show a significantly better prognosis compared with T1b. T1b glottic cancers are much more likely to be treated with primary radiotherapy compared with surgery.Level of Evidence: 4 Laryngoscope, 132:2187ā2193, 2022